Tidepath

Amylin drugs

Pramlintide

Also called Symlin, SymlinPen, pramlintide acetate

Symlin: a lab-made version of amylin, the hormone released with insulin, injected before each major meal1.

Status
Approved by the FDA in 2005 for diabetes alongside mealtime insulin, as Symlin, and now listed by the FDA as discontinued12.
How it's taken
By injection

What it is

Symlin is the brand name of pramlintide, a lab-made version of amylin1. Amylin is a hormone the pancreas releases together with insulin when you eat1. A lab-made version of a hormone like this is called an analogue1. In studies in people, pramlintide slowed how fast food leaves the stomach, lowered the rise in glucagon after meals and led people to eat less1. Glucagon is a hormone that makes the liver release sugar1. Human amylin itself tends to clump into fibres, which makes it hard to turn into a medicine4. Symlin's approval covers people with type 1 or type 2 diabetes who use mealtime insulin, when well-adjusted insulin hasn't brought their blood sugar under control1. Weight loss isn't part of its approval1.

What makes it distinct

Pramlintide clears from the body quickly: its half-life, the time it takes for half a dose to clear, is about 48 minutes in healthy people, and the label has it injected right before each major meal1.

What the evidence shows

The trials on Symlin's label were placebo-controlled, meaning some people got a dummy injection for comparison1. In type 1 diabetes there were three trials lasting 26 to 52 weeks, plus one study that raised the dose step by step1. In type 2 diabetes there were two trials, of 26 and 52 weeks1. People in them were also using insulin1. The trials measured HbA1c (a blood test for average blood sugar over the past few months) and body weight, and most also tracked insulin doses1. In the trials that kept insulin doses as steady as possible, HbA1c fell more on pramlintide than on placebo1. In the study that raised the dose step by step, insulin doses could be adjusted: HbA1c fell about the same in both groups, and people on pramlintide used less mealtime insulin1. On average, body weight went down slightly on pramlintide and rose slightly on placebo1.

Open questions

  • How long any remaining Symlin supply lasts. The FDA's database of approved drugs lists it as discontinued, and our sources don't say whether pharmacies can still get it2.
  • What it does for weight over the long term outside diabetes. It has been tested for weight in people with obesity, including a placebo-controlled study with an extension that ran to a year, but its approval covers only diabetes15.
  • Effects on heart attacks, strokes or other long-term outcomes. The trials on its label measured blood sugar, insulin doses and weight1.

Worth knowing

Symlin's label carries a boxed warning, printed in a box at the top of the label: used with insulin, it raises the risk of severe low blood sugar (hypoglycemia), particularly in type 1 diabetes1.

Sources

  1. SYMLIN (pramlintide acetate) injection, FDA prescribing information (DailyMed, AstraZeneca, revised 12/2019)
  2. Drugs@FDA: NDA 021332, SYMLIN (pramlintide acetate)
  3. Kruse T et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem 2021;64(15):11183-11194. PMID 34288673
  4. Smith SR et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008;31(9):1816-1823. PMID 18753666

More in Amylin drugs